Patrick M. Durbin Sells 6,000 Shares of Thermo Fisher Scientific Inc. (TMO) Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) insider Patrick M. Durbin sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $217.55, for a total value of $1,305,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Thermo Fisher Scientific Inc. (NYSE TMO) opened at $200.18 on Friday. The company has a market capitalization of $79,850.00, a price-to-earnings ratio of 35.75, a P/E/G ratio of 1.52 and a beta of 1.11. Thermo Fisher Scientific Inc. has a fifty-two week low of $151.74 and a fifty-two week high of $226.44. The company has a current ratio of 1.35, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, topping the Zacks’ consensus estimate of $2.66 by $0.13. The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $5.72 billion. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. Thermo Fisher Scientific’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period last year, the company posted $2.41 earnings per share. analysts anticipate that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be paid a $0.17 dividend. The ex-dividend date is Wednesday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a dividend yield of 0.34%. Thermo Fisher Scientific’s payout ratio is presently 10.71%.

A number of research analysts have recently weighed in on the company. Morgan Stanley raised their target price on Thermo Fisher Scientific from $223.00 to $227.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Barclays raised their target price on Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Leerink Swann restated an “outperform” rating and issued a $239.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Thursday, February 1st. They noted that the move was a valuation call. ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Bank of America raised their target price on Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $220.50.

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 2.4% in the second quarter. Vanguard Group Inc. now owns 26,600,394 shares of the medical research company’s stock valued at $4,640,970,000 after buying an additional 629,093 shares during the period. BlackRock Inc. raised its stake in shares of Thermo Fisher Scientific by 1.6% in the second quarter. BlackRock Inc. now owns 23,355,469 shares of the medical research company’s stock valued at $4,074,828,000 after buying an additional 366,584 shares during the period. Capital Research Global Investors raised its stake in shares of Thermo Fisher Scientific by 29.8% in the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock valued at $3,019,185,000 after buying an additional 3,973,136 shares during the period. Capital World Investors raised its stake in shares of Thermo Fisher Scientific by 6.1% in the second quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock valued at $2,051,721,000 after buying an additional 671,637 shares during the period. Finally, Longview Partners Guernsey LTD raised its stake in shares of Thermo Fisher Scientific by 6.8% in the fourth quarter. Longview Partners Guernsey LTD now owns 4,876,890 shares of the medical research company’s stock valued at $926,024,000 after buying an additional 311,977 shares during the period. Hedge funds and other institutional investors own 86.31% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Patrick M. Durbin Sells 6,000 Shares of Thermo Fisher Scientific Inc. (TMO) Stock” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://sportsperspectives.com/2018/02/10/patrick-m-durbin-sells-6000-shares-of-thermo-fisher-scientific-inc-tmo-stock.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply